• Latest Posts

IOME Bio claims breakthrough in cancer research

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Next-generation small molecules hold promise for immunotherapy

DeuterOncology closes financing round to start lung cancer study

ImaginAb launches trial to study neoadjuvant immunotherapy

Interview 29 Nov 2022

LAG-3: The next big checkpoint inhibitor target


Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

LG Chem renews license triggering $2M payment to Avacta

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors